John B Taylor

Expanding the landscape of covalent drug discovery: irreversible targeting of non-cysteine residues.

Covalent inhibitors have re-emerged as a powerful class of therapeutics due to their prolonged target engagement, ability to decouple pharmacokinetic availability from pharmacodynamic outcome, potential for high selectivity and ability to modulate traditionally 'undruggable' targets. Historically, cysteine residues hav...